Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KORU Medical Systems, Inc. - Common Stock (NQ:KRMD)

3.465 +0.055 (+1.61%)
Streaming Delayed Price Updated: 3:22 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about KORU Medical Systems, Inc. - Common Stock

< Previous 1 2 3 4 Next >
KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter
From KORU Medical Systems
Via Business Wire
KORU Medical Systems to Participate in Piper Sandler’s 36th Annual Healthcare Conference
From KORU Medical Systems
Via Business Wire
KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Participate in Upcoming Investor Conferences
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference
From KORU Medical Systems
Via Business Wire
KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference
From KORU Medical Systems
Via Business Wire
KORU Medical Systems, Inc Announces Leadership Changes to Support Growth Agenda
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge® Infusion System in Japan
From KORU Medical Systems, Inc.
Via Business Wire
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
From KORU Medical Systems, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.